Skip to main content
. Author manuscript; available in PMC: 2020 Mar 18.
Published in final edited form as: Mol Cancer Ther. 2019 Aug 6;18(11):1937–1946. doi: 10.1158/1535-7163.MCT-18-0985

Figure 5. NADH/NAD+ ratio reduced by incubation with CB-839 was rescued by DMKG.

Figure 5.

(A) A schematic depiction of the reduction of 1-13C pyruvate to 1-13C lactate through lactate dehydrogenase. (B) The NADH/NAD+ ratio was quantified by using bioluminescence assay after no treatment (control) or treatment with 0.1% DMSO or 1 μM CB-839 for 12 hours. The experiment included six replicates of the CB-839 treatment and four to six replicates for no treatment or 0.1% DMSO controls. Differences between treatment groups were analyzed for statistical significance by one-way ANOVA. (C) The NADH/NAD+ value was quantified after no treatment or treatment with 0.1% DMSO, 1 μM CB-839, or 1 μM CB-839 + 4 mM DMKG for 72 hours. The experiment included seven replicates per treatment group. Statistical significance of differences between treatment groups were determined by one-way ANOVA, *P < 0.0001.